Equifax stock falls as company says it's feeling effect of weaker mortgage demand
By Bill Peters
Credit-scoring company cites 'strong non-mortgage revenue growth' however
Shares of Equifax fell after hours on Wednesday after the credit-scoring giant forecast second-quarter revenue that missed expectations and said it expected a continued drop in mortgage inquiries this year.
The company, one of the three big ones that rates borrowers' credit quality for lenders, made that forecast as the housing market stalls out under high home prices and interest rates.
Equifax (EFX) said it expected second-quarter revenue of $1.41 billion to $1.43 billion. That was below FactSet forecasts for $1.44 billion.
The company said it was sticking with its full-year forecast for sales of $5.72 billion and adjusted earnings per share of $7.35. However, the company said its outlook "reflects an expectation of a decline of about 11% in our 2024 U.S. mortgage-credit inquiries."
For its first quarter, Equifax reported net income of $124.9 million, or $1 a share, compared with $112.4 million, or 91 cents a share, in the same quarter last year. Adjusted earnings per share came in at $1.50.
Equifax reported revenue of $1.389 billion, up 7% year over year.
Analysts polled by FactSet expected adjusted earnings per share of $1.44, on revenue of $1.4 billion.
Shares fell 9.5% after hours on Wednesday.
The company said that its non-mortgage revenue amounted to about 80% of revenue overall during the quarter. Chief Executive Mark Begor said outside of mortgages, the business remained strong.
In the company's earnings release, he said: "We have strong momentum in 2024 and are confident in the future of the new Equifax as we deliver strong non-mortgage revenue growth, move towards completion of our cloud transformation, leverage our new cloud capabilities to accelerate new product roll-outs that 'only Equifax' can provide, and invest in new products, data, analytics and AI capabilities, which are expected to drive growth in 2024 and beyond."
-Bill Peters
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
04-17-24 2052ET
Copyright (c) 2024 Dow Jones & Company, Inc.-
How Anti-Obesity Drugs Are Innovating the Healthcare Market
-
What’s Happening In the Markets This Week
-
Why Immigration Has Boosted Job Gains and the Economy
-
What to Invest in During High Inflation
-
Never Mind Market Efficiency: Are the Markets Sensible?
-
Starbucks Stock Could Use a Pick-Me-Up After Big Selloff; Is it a Buy?
-
5 Cheap Stocks to Buy From an Attractive Part of the Market
-
Markets Brief: All Eyes On Inflation
-
After Earnings, Is Lyft Stock a Buy, a Sell, or Fairly Valued?
-
8 Stock Picks in the Apparel Industry
-
Baidu Earnings: Advertising Weakness Offset by Continued Growth In Cloud Business
-
Going Into Earnings, Is Target Stock a Buy, a Sell, or Fairly Valued?
-
Walmart Earnings: Low Prices and Strong Digital Presence Drive Market Share Gains
-
After Earnings and a Big Selloff, Is Shopify Stock a Buy, a Sell, or Fairly Valued?
-
Cisco Earnings: Positive Guidance and Splunk Inclusion Align With Our Long-Term Thesis
-
3 Warren Buffett Stocks to Buy After Berkshire Hathaway’s Just-Released 13F Filing